Abstract
Hypertension prevalence is more than 30% in the general population and may be as high as 50% in some populations with mental illness. It is defined using cutoffs for systolic and diastolic blood pressure (SBP and DBP) that vary based on age and certain medical conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253–9.
Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, et al. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009;53(4):631–8.
Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59(10):502–8.
Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25(2):132–40.
Woo YS, Kim W, Chae JH, Yoon BH, Bahk WM. Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry. 2009;10(4 Pt 2):420–5.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.
Author information
Authors and Affiliations
Appendix
Appendix
Guidelines from Joint National Commission (JNC-8) [6]
Thiazide diuretics , calcium channel blockers (CCBs) , angiotensin-converting enzyme inhibitors (ACEIs) , or angiotensin receptor blockers (ARBs) are all considered first-line medications for hypertension treatment |
For black patients, including those with diabetes, CCBs or thiazide diuretics should be first-line medications |
For all patients with chronic kidney disease, regardless of race or diabetes status, ACEIs or ARBs should be included in antihypertensive treatment |
Beta blockers should only be considered after thiazine diuretics, CCBs, ACEIs, ARBs, unless other indications like ischemic heart disease or heart failure are present |
If BP is not at goal after 1 month on medication, dose should be raised or second agent added; medications should be added until goal BP is reached |
Commonly used medications for hypertension
Medication class | Mechanism of action | Comments |
---|---|---|
Thiazide diuretics Hydrochlorothiazide Chlorthalidone | Inhibit sodium transport in the distal renal tubule | Serum potassium should be monitored |
ACEI Lisinopril Enalapril Captopril | Inhibit conversion of angiotensin I to II resulting in vasodilation and reduced sympathetic activity | Renal function and serum potassium should be monitored |
ARB Losartan Candesartan Valsartan | Block angiotensin II receptors in blood vessels resulting in vasodilation and reduced sympathetic activity | Generally only indicated if ACEIs are not tolerated (e.g., cough occurs with ACEIs and not ARBs) |
CCBs Dihydropyridine Amlodipine Nondihydropyridine Verapamil Diltiazem | Regulate calcium influx into vascular smooth muscle cells and reduce vascular resistance | No lab monitoring required Nondihydropyridines generally used only with additional indications (e.g., atrial fibrillation) |
Beta blockers Metoprolol Atenolol Carvedilol | Block beta receptors in blood vessels and reduce sympathetic tone | Not used unless additional indications (e.g., atrial fibrillation, angina, heart failure) and first-line agents already used Metoprolol and atenolol are cardioselective and preferred in obstructive lung disease |
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Annamalai, A. (2017). Hypertension and Acute Hypertensive Crisis. In: Medical Management of Psychotropic Side Effects. Springer, Cham. https://doi.org/10.1007/978-3-319-51026-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-51026-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-51024-8
Online ISBN: 978-3-319-51026-2
eBook Packages: MedicineMedicine (R0)